Skip to content

FP7H2020HORIZON

Glaxosmithkline Research & Development Limited

Country
GBUnited Kingdom
Defence projects
0
Projects, all programmes
87
As coordinator
7
EU contribution (CORDIS)
EUR 2,550,777
Active
2008 to 2026

Projects

87 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
INNODIATranslational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – Sofia ref.: 115797H20202015ParticipantEUR 0
ADAPT-SMARTAccelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890H20202015ParticipantEUR 0
COMBACTE-CARECombatting Bacterial Resistance in Europe - Carbapenem ResistanceFP72015ParticipantNot stated
IPIEIntelligent Assessment of Pharmaceutical in the EnvironmentFP72015ParticipantNot stated
COMBACTE-MAGNETCombatting Bacterial Resistance in Europe - Molecules against Gram Negative InfectionsFP72015ParticipantNot stated
WEB-RADRRecognising Adverse Drug ReactionsFP72014ParticipantNot stated
ENABLEEuropean Gram Negative Antibacterial EngineFP72014CoordinatorNot stated
DRIVE-ABDRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USEFP72014ParticipantNot stated
SPRINTTSarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategiesFP72014ParticipantNot stated
COMBACTE-NETCombatting Bacterial Resistance in EuropeFP72013ParticipantNot stated
EARIPEuropean Asthma Research and Innovation PartnershipFP72013ParticipantNot stated
GETREALIncorporating real-life clinical data into drug developmentFP72013CoordinatorNot stated
TRANSLOCATIONMolecular basis of the outer membrane permeabilityFP72013CoordinatorNot stated
EMIFEuropean Medical Information FrameworkFP72013ParticipantNot stated
EUPATIEuropean Patients' Academy on Therapeutic InnovationFP72012ParticipantNot stated
ABIRISKAnti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the riskFP72012ParticipantNot stated
COMPACTCollaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular TargetsFP72012ParticipantNot stated
MEDIASRESNovel Statistical Methodology for Diagnostic/Prognostic and Therapeutic Studies and Systematic ReviewsFP72012ParticipantEUR 280,861
ETRIKSDelivering European Translational Information & Knowledge Management ServicesFP72012ParticipantNot stated
K4DDKinetics for Drug Discovery (K4DD)FP72012ParticipantNot stated

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.